SecurityAYTU / Aytu BioScience, Inc. (054754106)
IndustryPharmaceutical Preparations
Institutional Owners2
Institutional Shares709,313 - 39.38%
Common Shares Outstanding1,801,411 shares (as of 2018-06-30)
Institutional Value$ 186,000 USD

Institutional Stock Ownership and Shareholders

AYTU / Aytu BioScience, Inc. Institutional Ownership

Aytu BioScience, Inc. (NASDAQ:AYTU) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 709,313 shares. Largest shareholders include Sabby Management, LLC, and Barclays Plc.
Aytu BioScience, Inc. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR Sabby Management, LLC 709,312 186
2018-08-14 13F-HR BARCLAYS PLC 1 1 0.00 0 0
2018-07-20 13F-HR MCF Advisors LLC 357,142 0 -100.00 227 0 -100.00

Related News Stories

New Age Beverages Stock Surges on CFO Hire

2018-10-13 investorplace
New Age Beverages stock was on the rise today following news that it is getting a new CFO. (69-5)

New Age Beverages Corporation Appoints Gregory A. Gould as Chief Financial and Administrative Officer

2018-10-12 accesswire
DENVER, CO / ACCESSWIRE / October 12, 2018 / NEW AGE BEVERAGES CORPORATION (NASDAQ: NBEV), the Colorado-based organic, natural and healthy functional beverage company focused on becoming the world's leading healthy beverage company, today announced the appointment of Gregory A. Gould as its new Chief Financial and Administrative Officer. (69-1)

Aytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS(R) for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization

2018-10-11 accesswire
U.S. Patent Number 10,088,466 is Company's First United States Patent Covering MiOXSYS for Male Infertility Assessment (48-8)

Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

2018-10-10 accesswire
ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of an underwritten public offering on October 9, 2018, with total gross proceeds of $15.2 million which includes the full exercise of the underwriters' over-allotment option to purchase additional shares and warrants, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. (48-0)

Drug Prices Mostly Continue to Climb, Despite Trump's Promises

2018-10-10 biospace
Associated Press (AP) recently analyzed and published data regarding brand-name prescription drug prices. This was largely in response to President Donald Trump’s promises during the presidential campaign and in a May policy announcement that he would drive down drug prices. In fact, at the end of May, Trump promised pharma companies would be announcing “massive” voluntary drug prices within two weeks. (49-0)

CUSIP: 054754106